A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

(2016) Fernanda G. Herrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation

(2016) Lisa Deloch et al.   Frontiers in Oncology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Emerging immunotherapies for bladder cancer

(2015) Joseph W. Kim et al.   CURRENT OPINION IN ONCOLOGY

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

(2015) Ines Chevolet et al.   Journal of Translational Medicine

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy

(2015) Katrien De Wolf et al.   OncoImmunology

Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma

(2015) I Chevolet et al.   OncoImmunology

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up

(2014) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Stereotactic body radiotherapy for multisite extracranial oligometastases

(2011) Joseph K. Salama et al.   CANCER

Stereotactic body radiation therapy: The report of AAPM Task Group 101

(2010) Stanley H. Benedict et al.   MEDICAL PHYSICS

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER